YARROW BIOSCIENCE, INC. Selling, General and Administrative Expense
YARROW BIOSCIENCE, INC. (YARW) reported Selling, General and Administrative Expense of $3.03 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2023-11-13
- YARROW BIOSCIENCE, INC. selling, general and administrative expense for the quarter ending 2023-09-30 was $3.03M, a 23.37% decline year-over-year.
- YARROW BIOSCIENCE, INC. selling, general and administrative expense for the quarter ending 2023-06-30 was $3.22M, a 25.20% decline year-over-year.
- YARROW BIOSCIENCE, INC. selling, general and administrative expense for the quarter ending 2023-03-31 was $3.24M, a 26.65% decline year-over-year.
- YARROW BIOSCIENCE, INC. selling, general and administrative expense for the quarter ending 2022-12-31 was $3.71M, a 22.61% decline year-over-year.
- YARROW BIOSCIENCE, INC. selling, general and administrative expense for fiscal 2022 was $16.39M, a 19.27% decline from fiscal 2021.
- YARROW BIOSCIENCE, INC. selling, general and administrative expense for fiscal 2021 was $20.30M, a 77.33% decline from fiscal 2020.
- YARROW BIOSCIENCE, INC. selling, general and administrative expense for fiscal 2020 was $89.54M, a 98.48% increase from fiscal 2019.
- YARROW BIOSCIENCE, INC. selling, general and administrative expense for fiscal 2019 was $45.11M, a 221.94% increase from fiscal 2018.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2023-09-30 | $3.03M 10-Q · filed 2023-11-13 | $6.25M derived: sum of 2 quarters · filed 2023-11-13 | $9.49M 10-Q · filed 2023-11-13 | $13.20M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2023-06-30 | $3.22M 10-Q · filed 2023-08-14 | $6.46M 10-Q · filed 2023-08-14 | $10.17M derived: sum of 3 quarters · filed 2023-08-14 | $14.13M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2023-03-31 | $3.24M 10-Q · filed 2023-05-11 | $6.95M derived: sum of 2 quarters · filed 2023-05-11 | $10.90M derived: sum of 3 quarters · filed 2023-11-13 | $15.21M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-12-31 | $3.71M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $7.67M derived: sum of 2 quarters · filed 2023-11-13 | $11.97M derived: sum of 3 quarters · filed 2023-11-13 | $16.39M 10-K · filed 2023-03-14 | ||||
| 2022-09-30 | $3.95M 10-Q · filed 2023-11-13 | $8.26M derived: sum of 2 quarters · filed 2023-11-13 | $12.68M 10-Q · filed 2023-11-13 | $17.47M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | $4.30M 10-Q · filed 2023-08-14 | $8.72M 10-Q · filed 2023-08-14 | $13.52M derived: sum of 3 quarters · filed 2023-08-14 | $18.50M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $4.42M 10-Q · filed 2023-05-11 | $9.21M derived: sum of 2 quarters · filed 2023-05-11 | $14.20M derived: sum of 3 quarters · filed 2023-05-11 | $18.98M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $4.79M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $9.78M derived: sum of 2 quarters · filed 2023-03-14 | $14.57M derived: sum of 3 quarters · filed 2023-03-14 | $20.30M 10-K · filed 2023-03-14 | $54.48M 10-K · filed 2022-03-17 | |||
| 2021-09-30 | $4.98M 10-Q · filed 2022-11-14 | $13.83M 10-Q · filed 2021-11-10 | $9.77M derived: sum of 2 quarters · filed 2022-11-14 | $15.50M 10-Q · filed 2022-11-14 | $46.28M 10-Q · filed 2021-11-10 | $33.41M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $4.79M 10-Q · filed 2022-08-12 | $15.84M 10-Q · filed 2021-08-12 | $10.52M 10-Q · filed 2022-08-12 | $32.45M 10-Q · filed 2021-08-12 | $28.42M derived: sum of 3 quarters · filed 2022-08-12 | $48.19M derived: sum of 4 quarters · filed 2022-08-12 | ||
| 2021-03-31 | $5.73M 10-Q · filed 2022-05-12 | $16.62M 10-Q · filed 2021-05-06 | $23.64M derived: sum of 2 quarters · filed 2022-05-12 | $43.40M derived: sum of 3 quarters · filed 2022-05-12 | $69.86M derived: sum of 4 quarters · filed 2022-05-12 | |||
| 2020-12-31 | $17.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $37.67M derived: sum of 2 quarters · filed 2022-03-17 | $64.13M derived: sum of 3 quarters · filed 2022-03-17 | $89.54M 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | $19.77M 10-Q · filed 2021-11-10 | $46.23M derived: sum of 2 quarters · filed 2021-11-10 | $71.64M 10-Q · filed 2021-11-10 | $93.86M derived: sum of 4 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | $26.46M 10-Q · filed 2021-08-12 | $51.87M 10-Q · filed 2021-08-12 | $74.09M derived: sum of 3 quarters · filed 2021-08-12 | $84.84M derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | $25.41M 10-Q · filed 2021-05-06 | $47.63M derived: sum of 2 quarters · filed 2021-05-06 | $58.38M derived: sum of 3 quarters · filed 2021-05-06 | $65.19M derived: sum of 4 quarters · filed 2021-05-06 | ||||
| 2019-12-31 | $22.22M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $32.97M derived: sum of 2 quarters · filed 2021-03-04 | $39.77M derived: sum of 3 quarters · filed 2021-03-04 | $45.11M 10-K · filed 2021-03-04 | ||||
| 2019-09-30 | $10.75M 10-Q · filed 2020-11-05 | $17.55M derived: sum of 2 quarters · filed 2020-11-05 | $22.89M 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | $6.80M 10-Q · filed 2020-08-06 | $12.15M 10-Q · filed 2020-08-06 | ||||||
| 2019-03-31 | $5.34M 10-Q · filed 2020-05-11 | |||||||
| 2018-12-31 | $14.01M 10-K · filed 2021-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |